Drug Trial Radar · NCT07854509
A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI Failure
Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
110
Planned (sponsor's estimate)
Start
Oct 15, 2026
Primary completion
Dec 30, 2027
Study completion Dec 30, 2029
Sponsor
- Lead sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, Phase II clinical study to evaluate the safety, tolerability, and efficacy of SKB264 in combination with SKB118 in participants with locally advanced or metastatic non-squamous NSCLC harboring EGFR-sensitizing mutations who have failed EGFR-TKI therapy. The study includes a dose escalation phase and an expansion phase.
Conditions
- Non-Squamous Non-Small Cell Lung Cancer
Interventions
SKB264+SKB118Drug
Administered by intravenous infusion on Day 1 and Day 15 of each 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The safety of SKB264 in combination with SKB118 in participants with non-squamous non-small cell lung cancer (NSCLC)Time frame: From enrollment to the end of treatment at 24 months
- ORR(objective response rate)Time frame: From enrollment to the end of treatment at 24 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.